Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
On 1 March 2009, a new reimbursement system was introduced by the Ministry of Health of Iceland regarding drugs to treat hyperlipidaemia. The Social Insurance Administration was only authorised to reimburse 10 and 20 mg simvastatin unless patients were eligible to receive a medical card from the Soc...
Published in: | Scandinavian Journal of Public Health |
---|---|
Main Authors: | , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
SAGE Publications
2013
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/299247 https://doi.org/10.1177/1403494812458991 |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/299247 |
---|---|
record_format |
openpolar |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/299247 2023-05-15T16:47:14+02:00 Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. Gizurarson, Sveinbjörn Björnsdóttir, Linda Rós Einarsdóttir, Rannveig Halldórsson, Matthías Andersen, Karl Faculty of Pharmaceutical Sciences, School of Health Science, University of Iceland, Hofsvallagata 53, Reykjavik, Iceland. 2013-08-20 http://hdl.handle.net/2336/299247 https://doi.org/10.1177/1403494812458991 en eng SAGE Publications http://dx.doi.org/10.1177/1403494812458991 http://sjp.sagepub.com/content/40/7/663 Scand J Public Health 2012, 40(7):663-7 1651-1905 23027893 doi:10.1177/1403494812458991 http://hdl.handle.net/2336/299247 Scandinavian journal of public health Archived with thanks to Scandinavian journal of public health National Consortium - Landsaðgangur Adult Aged 80 and over Anticholesteremic Agents Cholesterol Female Fluorobenzenes Follow-Up Studies Heptanoic Acids Humans Hyperlipidemias Iceland Male Middle Aged Pravastatin Pyrimidines Pyrroles Reimbursement Mechanisms Simvastatin Social Security Sulfonamides Treatment Outcome Article 2013 ftlandspitaliuni https://doi.org/10.1177/1403494812458991 2022-05-29T08:21:51Z On 1 March 2009, a new reimbursement system was introduced by the Ministry of Health of Iceland regarding drugs to treat hyperlipidaemia. The Social Insurance Administration was only authorised to reimburse 10 and 20 mg simvastatin unless patients were eligible to receive a medical card from the Social Insurance Administration. The purpose of this study was to evaluate the influence of this reimbursement regulation on the clinical outcome. MATERIALS AND METHODS: Patients that received hyperlipidaemia treatment and were admitted to the cardiac ward were enrolled. The criteria were that the patients had been admitted 1 year prior to the regulation change and were using other statins than simvastatin. RESULTS: Out of 233 eligible patients 170 (73%) reached the treatment goal before the switch. After the switch, only 126 (54%) reached their goal (p<0.05). Total cholesterol was found to be increased after the switch by a mean of 0.48 mmol/l (range 3.90-5.53 mmol/l, p<0.001). Low-density lipoprotein cholesterol increased by a mean of 0.48 mmol/l (range 1.62-3.11, p<0.001). The level of triglycerides did not change significantly. Before the introduction of the new regulations, 73% of subjects were well controlled, but after 1 March 2009, this figure dropped to 46% (37% decrease). CONCLUSIONS: In order to lower costs for subsidising drugs, a switch to simvastatin from other cholesterol-lowering drugs was implemented (by the Ministry of Health of Iceland). The result was a significant and unwanted increase in cholesterol levels among patients with heart disease. The reason seems to be inaccurate prescriptions due to lack of competence among physicians and pharmacists. The use of "one drug fits all" does not comply here. On 1 March 2009, a new reimbursement system was introduced by the Ministry of Health of Iceland regarding drugs to treat hyperlipidaemia. The Social Insurance Administration was only authorised to reimburse 10 and 20 mg simvastatin unless patients were eligible to receive a medical card from ... Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive Scandinavian Journal of Public Health 40 7 663 667 |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
Adult Aged 80 and over Anticholesteremic Agents Cholesterol Female Fluorobenzenes Follow-Up Studies Heptanoic Acids Humans Hyperlipidemias Iceland Male Middle Aged Pravastatin Pyrimidines Pyrroles Reimbursement Mechanisms Simvastatin Social Security Sulfonamides Treatment Outcome |
spellingShingle |
Adult Aged 80 and over Anticholesteremic Agents Cholesterol Female Fluorobenzenes Follow-Up Studies Heptanoic Acids Humans Hyperlipidemias Iceland Male Middle Aged Pravastatin Pyrimidines Pyrroles Reimbursement Mechanisms Simvastatin Social Security Sulfonamides Treatment Outcome Gizurarson, Sveinbjörn Björnsdóttir, Linda Rós Einarsdóttir, Rannveig Halldórsson, Matthías Andersen, Karl Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. |
topic_facet |
Adult Aged 80 and over Anticholesteremic Agents Cholesterol Female Fluorobenzenes Follow-Up Studies Heptanoic Acids Humans Hyperlipidemias Iceland Male Middle Aged Pravastatin Pyrimidines Pyrroles Reimbursement Mechanisms Simvastatin Social Security Sulfonamides Treatment Outcome |
description |
On 1 March 2009, a new reimbursement system was introduced by the Ministry of Health of Iceland regarding drugs to treat hyperlipidaemia. The Social Insurance Administration was only authorised to reimburse 10 and 20 mg simvastatin unless patients were eligible to receive a medical card from the Social Insurance Administration. The purpose of this study was to evaluate the influence of this reimbursement regulation on the clinical outcome. MATERIALS AND METHODS: Patients that received hyperlipidaemia treatment and were admitted to the cardiac ward were enrolled. The criteria were that the patients had been admitted 1 year prior to the regulation change and were using other statins than simvastatin. RESULTS: Out of 233 eligible patients 170 (73%) reached the treatment goal before the switch. After the switch, only 126 (54%) reached their goal (p<0.05). Total cholesterol was found to be increased after the switch by a mean of 0.48 mmol/l (range 3.90-5.53 mmol/l, p<0.001). Low-density lipoprotein cholesterol increased by a mean of 0.48 mmol/l (range 1.62-3.11, p<0.001). The level of triglycerides did not change significantly. Before the introduction of the new regulations, 73% of subjects were well controlled, but after 1 March 2009, this figure dropped to 46% (37% decrease). CONCLUSIONS: In order to lower costs for subsidising drugs, a switch to simvastatin from other cholesterol-lowering drugs was implemented (by the Ministry of Health of Iceland). The result was a significant and unwanted increase in cholesterol levels among patients with heart disease. The reason seems to be inaccurate prescriptions due to lack of competence among physicians and pharmacists. The use of "one drug fits all" does not comply here. On 1 March 2009, a new reimbursement system was introduced by the Ministry of Health of Iceland regarding drugs to treat hyperlipidaemia. The Social Insurance Administration was only authorised to reimburse 10 and 20 mg simvastatin unless patients were eligible to receive a medical card from ... |
author2 |
Faculty of Pharmaceutical Sciences, School of Health Science, University of Iceland, Hofsvallagata 53, Reykjavik, Iceland. |
format |
Article in Journal/Newspaper |
author |
Gizurarson, Sveinbjörn Björnsdóttir, Linda Rós Einarsdóttir, Rannveig Halldórsson, Matthías Andersen, Karl |
author_facet |
Gizurarson, Sveinbjörn Björnsdóttir, Linda Rós Einarsdóttir, Rannveig Halldórsson, Matthías Andersen, Karl |
author_sort |
Gizurarson, Sveinbjörn |
title |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. |
title_short |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. |
title_full |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. |
title_fullStr |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. |
title_full_unstemmed |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. |
title_sort |
clinical consequences following regulatory changes in respect to reimbursement of statins cost by the icelandic social insurance administration. |
publisher |
SAGE Publications |
publishDate |
2013 |
url |
http://hdl.handle.net/2336/299247 https://doi.org/10.1177/1403494812458991 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://dx.doi.org/10.1177/1403494812458991 http://sjp.sagepub.com/content/40/7/663 Scand J Public Health 2012, 40(7):663-7 1651-1905 23027893 doi:10.1177/1403494812458991 http://hdl.handle.net/2336/299247 Scandinavian journal of public health |
op_rights |
Archived with thanks to Scandinavian journal of public health National Consortium - Landsaðgangur |
op_doi |
https://doi.org/10.1177/1403494812458991 |
container_title |
Scandinavian Journal of Public Health |
container_volume |
40 |
container_issue |
7 |
container_start_page |
663 |
op_container_end_page |
667 |
_version_ |
1766037315137830912 |